| DRUGS APPROVED FDA approves new product to treat rare genetic disease: Ruconest FDA Approves Rasuvo (methotrexate) Injection FDA Approves Salix-Pharming Angioedema Treatment |
 |
PRESS RELEASE: PSG Announces Launch of New Company: Intelligent Compliance Solutions (ICS) to Serve as a 340B Compliance Advisor
PSG - July 15, 2014
Pharmaceutical Strategies Group (PSG), announced that Intelligent Compliance Solutions (ICS) has been added as the newest member of the PSG family of companies. ICS was formed to address 340B program audit and compliance challenges faced by health care organizations.
Niacin could have risks as cholesterol therapy
USA TODAY - July 16, 2014
Niacin, a drug commonly prescribed to prevent stroke and heart attack, appears to add little benefit to the statins it is usually taken with, but it may cause significant risks, according to a new study and editorial in The New England Journal of Medicine.
15 Most Expensive Cities for Primary Care
Becker's Hospital Review - July 16, 2014
In Dallas, a patient can pay up to 23 times more than necessary for a lipid panel, according to a recent study by Castlight Health, a leading provider of enterprise healthcare cloud software. Examining the cost of common outpatient services in different cities, the Castlight study illuminates the wide range of primary care costs across the United States.
Supermaterial gives rejected drugs a new chance
Science Daily - July 22, 2014
More than 80 percent of all drug candidates in the pharma R&D suffer from poor solubility and are therefore rejected early in the drug discovery process. Now researchers show that a new material, Upsalite®, has great potential for development of new formulations of these rejected drugs. These findings could allow the pharma companies to open up large libraries of potent drug candidates earlier discarded due to solubility problems and try them again.
Arthritis Drug Shown to Slow Alzheimer’s
Drug Discovery & Development - July 17, 2014
A drug that is commonly used for arthritis has been shown to slow the progression of Alzheimer’s. A small randomized control study at the University of Southampton tested the drug Etanercept on patients with mild to moderate Alzheimer’s.
Popping Pills in America: Can the DEA Fix This?
Drugs.com - July, 2014
There's no doubt about it - the U.S. is a big consumer of prescription painkillers. In fact, in 2010 enough prescription painkillers were prescribed to medicate each American adult every four hours for an entire month.
AIDS Epidemic May Be Subsiding: Report
Drugs.com - July 16, 2014
A new United Nations report suggests that the AIDS epidemic might be waning: The number of new HIV infections worldwide is at a record low, AIDS-related deaths are down 35 percent, and more people with HIV are getting the lifesaving medications they need.
Study Finds Many Flu Patients Not Treated Appropriately
HealthDay News - July 17, 2014
Antiviral drugs aren't prescribed often enough for patients at high risk for flu complications, while too many of them receive unneeded antibiotics, a new study says.
D.C. appeals court strikes down ACA insurance subsidies for federal exchanges
Modern Healthcare - July 22, 2014
A federal appeals court has ruled the Obama administration cannot subsidize insurance premiums for nearly 7 million Americans, dealing a serious blow to the Affordable Care Act. The administration plans to appeal the ruling to a full panel of the left-leaning D.C. Circuit Court.
Medicare Modifies Controversial Hospice Drug Rule
Kaiser Health News - July 18, 2014
In response to strong criticism, Medicare officials are modifying rules intended to prevent the agency from paying twice for the same prescriptions for seniors receiving hospice care.
US breakthrough designation in IPF for Boehringer’s nintedanib
Boehringer Ingelheim via Business Wire - July 17, 2014
Boehringer Ingelheim today announced that for the first time the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy designation for a treatment in idiopathic pulmonary fibrosis (IPF), a devastating and fatal lung disease. Nintedanib* is an investigational therapy currently under FDA and European Medicines Agency (EMA) review for IPF.
Lucrative Drug Niche Sparks Legal Scramble
Wall Street Journal - July 20, 2014
The pharmaceutical industry's battle for dominance in the fast-growing and lucrative market for treatments of hepatitis C is prompting an unprecedented legal scramble.
Specialty drugs transform lives — but at a cost
Boston Globe - July 21, 2014
Expensive new specialty drugs offer hope to patients with rare and chronic illnesses but also leave many worrying about paying for them.
Firms that cut birth-control coverage must notify workers: White House
Modern Healthcare - July 18, 2014
If closely held companies want to nix their employees' insurance coverage of contraceptives, they can't do so in secret.
Arkansas stiff-arms CF patients seeking Vertex's $300K drug Kalydeco: WSJ
FiercePharma - July 17, 2014
The drug-pricing battle continues, but this time, Gilead Sciences' Sovaldi isn't at the center. That dubious honor goes to Vertex Pharmaceuticals' cystic fibrosis treatment Kalydeco. According to a lawsuit filed by three CF patients, Arkansas Medicaid officials are locking them out of Kalydeco treatment.
Preparing for the impact of pharmacy quality metrics
Drug Store News - July 21, 2014
The Centers for Medicare and Medicaid Services’ Five-Star Quality Rating System already is impacting how pharmacies think about their patients and their medication adherence programs, noted Samuel Stolpe, director of quality strategies for the Pharmacy Quality Alliance, during a Lunch and Learn session Monday at McKesson ideaShare called “When the Stars Align: Prepare Your Pharmacy For Success.”
Report: Patients facing growing challenges accessing orphan drugs
Drug Store News - July 14, 2014
Although the pace of approvals for new orphan drugs — medicines that treat relatively rare conditions — have increased in the United States and Europe in recent years, patients are facing growing challenges accessing those drugs, a newly completed study released last week by the Tufts Center for the Study of Drug Development at Tufts University has concluded.
Contact,
Kristin LaVitola
Marketing Director, PSG
Pharmaceutical Strategies Group (PSG)
Office: 972-244-8388
Email: KLavitola@PSGConsults.com
PSGNewsletter@PSGConsults.com
www.PSGConsults.com
 |
 |
 |